PharmaVoice quoted Associate Mitchell Clough in an article about a recent string of court losses for pharmaceutical companies in cases challenging drug price negotiations created under the Inflation Reduction Act, which could make their way to the Supreme Court docket soon.

“The industry has little incentive not to pursue Supreme Court review,” Clough said. “Although a circuit split would likely tee up the case even more clearly for the Court’s review, which could still be coming with the 5th Circuit, these are significant issues of constitutional law. Ultimately, the industry needs only one of their claims to work.”

Source

PharmaVoice